Dissolving oral clonazepam wafers in the acute treatment of prolonged seizures

J Child Neurol. 2010 Dec;25(12):1468-72. doi: 10.1177/0883073810368312. Epub 2010 Apr 22.

Abstract

Klonopin (clonazepam; Genentech Inc, South San Francisco, California) oral wafers are benzodiazepines with anticonvulsive and anxiolytic properties. Our institution has been prescribing clonazepam wafers for acute treatment of prolonged seizures for years. Patients' size determined dosing at 0.25, 0.5, 1, or 2 mg wafers. We proceeded to obtain evidence for efficacy. Hospital Institutional Review Board approval was obtained for anonymous patient survey. All children who had been prescribed clonazepam wafers over a 6-year period at our institution were mailed detailed questionnaires. Three hundred eighty-one questionnaires were mailed with 88 replies but only 56 with meaningful data. Average age was 12.1 years. There were 31 males. Efficacy was defined as stopping seizure within 10 minutes, >50% of the time. Thirty-eight of the 56 (68%) patients met this criterion. From these 38 patients, 19 (50%) had seizures stop within 1 minute. Overall results were comparable to Diastat (rectal diazepam; Valeant Pharmaceuticals International, Aliso Viejo, California). Clonazepam wafers are an effective acute therapy for prolonged seizures.

Publication types

  • Comparative Study

MeSH terms

  • Acute Disease
  • Administration, Oral
  • Adolescent
  • Adult
  • Age Factors
  • Anticonvulsants / administration & dosage*
  • Child
  • Child, Preschool
  • Clonazepam / administration & dosage*
  • Epilepsy / drug therapy*
  • Female
  • Humans
  • Male
  • Outcome Assessment, Health Care / methods*
  • Retrospective Studies
  • Status Epilepticus / drug therapy*
  • Surveys and Questionnaires / standards
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Anticonvulsants
  • Clonazepam